Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Poseida Therapeutics Inc | PSTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.00 | 07:32:21 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.00 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.54 - 4.27 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.00 | USD |
Poseida Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 192.98M | 96.49M | - | 64.7M | -123.43M | -1.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Poseida Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PSTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.92 | 2.92 | 1.87 | 2.15 | 779,548 | -0.92 | -31.51% |
| 1 Month | 3.06 | 3.35 | 1.87 | 2.70 | 574,690 | -1.06 | -34.64% |
| 3 Months | 3.29 | 4.27 | 1.87 | 3.31 | 755,282 | -1.29 | -39.21% |
| 6 Months | 2.34 | 4.27 | 1.83 | 3.03 | 809,344 | -0.34 | -14.53% |
| 1 Year | 2.37 | 4.27 | 1.54 | 2.64 | 826,548 | -0.37 | -15.61% |
| 3 Years | 8.67 | 11.10 | 1.54 | 3.85 | 576,670 | -6.67 | -76.93% |
| 5 Years | 17.00 | 17.62 | 1.54 | 4.85 | 533,211 | -15.00 | -88.24% |
Poseida Therapeutics Description
| Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet delivery technology. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours. |
